Host genetics and opportunistic fungal infections  by Pana, Z.-D. et al.
Host genetics and opportunistic fungal infections
Z.-D. Pana1, E. Farmaki2 and E. Roilides1
1) Infectious Diseases Unit, 3rd Department of Paediatrics, and 2) Laboratory of Clinical Immunology, 1st Department of Paediatrics, Faculty of Medicine,
Aristotle University School of Health Sciences, Thessaloniki, Greece
Abstract
Current knowledge on the human pathophysiology of fungal infections highlights the crucial role of genetic pitfalls in specific immunity
pathways that determine, together with other risk factors, the predisposition to and clinical outcome of fungal disease. In several studies,
associations between gene polymorphisms and genetic errors have been implicated in an immunodeficiency phenotype and an increased
incidence of opportunistic fungal diseases. The major challenge is to fully understand the complex interactions between genetic variations
and multiple factors, and their relative contributions to the final clinical fungal disease phenotype. The aim of this review is to present
updated knowledge on immunity genetics and susceptibility to medically relevant fungal diseases, such as those caused by Candida, Aspergillus,
and certain other more rare fungi.
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Introduction
Fungal infections remain a major cause of significant morbidity
and mortality among specific patient groups and of an
increased financial burden to the healthcare economics. One
major priority in the field is the extended identification of all
possible fungal-specific and host-specific factors for fungal
disease predisposition, which is crucial knowledge that could
‘refine’ the future management of these patients. A large panel
of well-defined clinical and laboratory parameters has been
implicated in the development, severity and outcome of
certain invasive fungal diseases (IFDs) in the immunocompro-
mised host.
On the other hand, significant variability has been reported
in the development and outcome of IFD among patients with
the same predisposing factors, implying an individualized
genetic pattern of susceptibility. Accumulating evidence has
recently shown that immune system genetic variations leading
to imbalances in both proinflammatory and anti-inflammatory
responses may predispose to fungal infections. Hence, it is
reasonable to speculate that genetic variations involved in
important pathways of the innate and adaptive immune
systems may represent a potential source of variability in
susceptibility to IFD.
These genetic variations, known also as single-nucleotide
polymorphisms (SNPs), refer to one of multiple alternative
forms within a nucleic acid sequence that occurs with
increased frequency (>1%) within a population and allows
evolution by natural selection. SNPs are perceived as equally
acceptable alternatives in a DNA sequence, and in most
cases their impact on a gene may not significantly influence
the activity of the encoded protein. Nevertheless, under
certain circumstances, even these minor effects may signif-
icantly influence susceptibility to human disease. In contrast,
mutations result from rare (<1%) genetic errors originating
from unrepaired errors in the DNA replication process.
These genetic errors can have an impact on the phenotype
of an organism, especially if they occur within the pro-
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/1469-0691.12800
tein-coding sequence of a gene. Mutations can be also
divided into hereditary or germline mutations, when the
error exists in the reproductive cells and can be passed from
generation to generation, and acquired or somatic mutations,
when the error occurs in the DNA of individual cells that
develop throughout a person’s life and is passed only to
direct descendants of those cells. For many pathological
conditions, there may even be different mutations in the
gene, which may cause the same disease with variations in
the phenotype. A few clinically relevant disorders may be the
result of only a single defective gene mutation, and are
called monogenetic disorders. These inherited diseases,
controlled by a single pair of alleles, are passed on from
one generation to another in a simple pattern according to
Mendel’s laws.
In recent years, variants in several immune-related SNPs
and inborn genetic errors of immunity associated with
monogenetic disorders have been proposed to affect immunity
against Candida and Aspergillus species by influencing commen-
salism, symbiosis, latency and dissemination of the fungi.
Selection of the appropriate candidate ‘key’ genes and their
polymorphisms remains a great challenge, and metagenomic
technologies hold promise for resolving questions regarding
the functional effects of crucial genes in IFD predisposition.
This review highlights the present knowledge on immunity
genetics and susceptibility to IFD.
Immune Genetic Profile and Aspergillosis
Innate immunity plays a significant role in the initial phase of
ingestion, killing and elimination of Aspergillus conidia. Further-
more, the local production of cytokines by activated macro-
phages and neutrophils seems to regulate proinflammatory
(Th1) and anti-inflammatory (Th2) immune reactions. Several
cytokine gene polymorphisms are considered to be candidate
prognostic biomarkers for Aspergillus infection (Table 1).
Cytokine functional gene polymorphisms (interleukin (IL)-10,
IL-15, transforming growth factor (TGF)-b1, tumour necrosis
factor (TNF)-a, and interferon (IFN)-c) have been evaluated in
patients with chronic cavitary pulmonary aspergillosis (CCPA)
and allergic bronchopulmonary aspergillosis (ABPA) [1]. Spe-
cific alleles have been more frequently detected in patients
suffering from invasive aspergillosis (IA), such as the IL-15
+13689A allele [1]. The presence of the IFN-c 874T>A
polymorphism as a single SNP or as a combined deficiency with
an SNP in Toll-the like receptor (TLR)-4 gene (1063A>G) has
shown a trend to cause increased susceptibility to IA [1,2].
CCPA patients have been genetically determined produce less
IL-10 and TGF-b1, owing to the frequent presence of the IL-10
1082G and TGF-b1 +869T alleles [1]. In patients undergoing
allogeneic stem cell transplantation (SCT), SNPs in the
promoter region of the IL-10 gene and an ACC haplotype
are independent protective markers for invasive pulmonary
aspergillosis (IPA), suggesting that the genotypic variability of
the IL-10 gene promoter region modulates the production of
IL-10 and indirectly influences the risk of developing IPA [3,4].
In particular, for the IL-10 1082(AA) genotype, the results
are rather controversial. According to Sainz et al., the IL-10
1082(AA) genotype is associated with resistance to the
development of IPA, whereas in another study the genotype
was associated with an increased risk of ABPA in patients with
cystic fibrosis [5].
A polymorphism in the IL-4 receptor gene plays a role in
the occurrence of ABPA [6]. Sainz et al. [7] evaluated the
role of IL-1 gene cluster polymorphisms in the pathogenesis
of, susceptibility to and resistance to IPA, and found that
specific haplotypes (VNTR2/–889C/–511T) were significantly
associated with the development of IPA, whereas others
(VNTR2/–889C/–511C) were associated with resistance. In a
recent study by Carvalho et al. [8], a prognostic role of IL-23
receptor gene polymorphism was found in patients undergo-
ing SCT, implying that donors with the R381Q haplotype
gave a protective effect against IA. In evaluation of the genetic
risk for developing IPA, IL-6 gene polymorphisms (promoter
at positions 174 (C/G) and 634 (G/C)) were not
significantly associated with an increased predisposition to
develop IPA [9].
Aswell as SNPs in other cytokine receptor genes, SNPs in the
TNF receptor 1 and TNF receptor 2 genes have been associ-
ated with IPA predisposition in two studies, owing to decreased
TNF expression [10,11]. SNPs in the gene encoding chemokine
ligand 10, which enhances chemokine secretion after Aspergillus
stimulation, seemed to influence susceptibility to IPA in alloSCT
patients [12]. A non-synonymous SNP in the gene encoding
plasminogen, a factor that binds to fungal cell wall of Aspergillus
fumigatus, affected the risk of developing IA in patients after SCT
[13]. An SNP in the gene encoding dectin-1 receptor, a major
receptor for fungal b-glucans on myeloid cells, leads to a
decreased Th17 response and seems to influence the presence
of IA in non-SCT patients but not the clinical course of IA in SCT
recipients [14]. However, in another study, this SNP increased
the risk of IA, with the risk being highest when the SNP was
detected simultaneously in both donor and recipient [15].
Finally, the carriage of several alleles of dectin-1 and DC-SIGN
polymorphisms increases the risk of IPA [16].
The role of genetic variations of TLR genes in IA predispo-
sition has been extensively evaluated, with partially contradic-
tory results. TLR-2 gene polymorphism has not been associated
with CCPA and IA in haematological patients after SCT [17,18].
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TABLE 1. Single-nucleotide polymorphisms (SNPs) and Aspergillus infection
Gene SNP
Patients/
controls
Aspergillus-related
disease Comments Reference
Mannose-binding
lectin (MBL)2
Codon 52
868C/T
10/82 CNPA Mutant MBL2 higher in CNPA patients than in controls
(70% vs. 25.6%) (p 0.004)
[23]
15/82 CCPA, ABPA T allele (p 0.020) and CT genotype (p 0.05) associated
with CCPA but not with ABPA
[22]
Codon 54
Allele B
23/52 IA No difference in mutant MBL2 genotype between patients
with aspergillosis and controls (44% vs. 34.8%) (p >0.05)
[21]
Intron
–1011A/G
11/84 ABPA Mutant SNP associated with allergic rhinitis in bronchial
asthma and ABPA (p <0.01)
[24]
Chemokine ligand
10 (C-X-C 10)
101C/T 51/49 IA after HSCT SNP associated with an increased risk of IA development
(p = 0.007 OR= 2.2 CI = 1.2–3.8)
[12]
1642C/G 39/46 IA after HSCT SNP associated with an increased risk of IA development
(p 0.003, OR 2.6. 95% CI 1.4–5.0)
[12]
1101A/G 52/44 IA after HSCT SNP associated with an increased risk of IA development
(p 0.001, OR 2.8, 95% CI 1.6–5.2)
[12]
Toll-like receptors (TLRs) TLR-4
239C/G
743A/G
22/105 IA after HSCT Presence of both recipient SNPs associated with IA
(p <0.001, OR 1.3, 95% CI 1.1–1.5)
[19]
TLR-6
745C/T
22/105 IA after HSCT SNP associated with IA (p <0.001, OR 1.3, 95%
CI 1.1–1.5)
[19]
TLR-4
1063A/G
44/64 IA after HSCT The combined presence of TLR-4 and IFN-c 874T>A
SNPs associated with increased susceptibility to IA
(p 0.04, OR 6.09, 95% CI 1.05–35.5)
[2]
TLR-4
1063A/G
103/263 IA after HSCT Donor TLR-4 haplotype (S3) associated with increased
risk of IA (p 0.020, OR 2.2, 95% CI 1.1–4.2)
[20]
TLR-4
1363C/T
103/263 IA after HSCT Donor TLR-4 haplotype (S4) associated with increased
risk of IA (p 0.002, OR 6.2, 95% CI 2.0–19.3)
[20]
TLR-4
1063A/G
40/80 CCPA Recipient SNPs associated with CCPA (p 0.003, OR 3.5,
95% CI 1.5–8.1)
[17]
TLR-9
1237C/T
22/80 ABPA SNP associated with ABPA (p 0.043, OR 2.5, 95% CI 1.0–
6.2)
[17]
Tumour necrosis
factor (TNF)-a
TNF-a
–308A/A
54/48 IA Lower frequency of TNF-a –308A/A genotype in IA
(p <0.01)
[1]
TNFR2
+676
322
IPA in haematological
patients
IPA associated with TNFR2 –322 SNP (p 0.029) but not
with TNFR2 +676 SNP (p >0.05)
[10]
Interleukin (IL) IL-10
1082A/G
819C/T
592A/C
9/96 IPA after HSCT Increased IPA dependent on IL-10 haplotype (p 0.031) [4]
IL-10 promoter SNPs independent predictive factors for
IPA (p 0.012, OR 9.3, 95% CI 1.6–52.8)
IL-10
1082A/G
119 colonized/
27 ABPA/232
Colonization with Aspergillus
fumigatus or ABPA in CF
IL-10 –1082GG genotype associated with A. fumigatus
colonization and ABPA in CF patients (p 0.020, OR 1.7,
95% CI 1.1–2.5)
[5]
IL-10
1082A/G
59/61 IPA in haematological
patients
IL-10 –1082AA associated with resistance to IPA
development (p 0.001)
[3]
IL-10 –1082A allele weakly associated with IPA
susceptibility (p 0.052, OR 1.7, 95% CI 1.0–2.9)
IL-10
–1082A/G
24 CCPA CCPA associated with lower frequency of IL-10 –1082G
allele (OR 0.38, p 0.0006) and G/G genotype (p <0.001)
[1]
IL-1b
511C/T
889C/T
59/51 IPA in haematological
patients
IL-1 and IL-1Ra SNPs not associated with IPA (p 0.56 and
p 0.68)
IL-1Ra VNTR2/889C/–511T haplotype associated with increased
susceptibility to IPA (p 0.02); VNTR2/–889C/–511C
haplotype associated with resistance to IPA (p 0.028)
[7]
IL-1Ra VNTR2/2 and IL1b(–511)T/T genotypes associated
with higher positive serum galactomannan percentage
than other genotypes (p 0.09)
IL-15
+13689
IA IA associated with higher frequency of IL-15 +13689A
allele (OR 2.37, p 0.0028) and A/A genotype (p <0.001)
[1]
IL-23R
IL-17A
IL-17F
IA in SCT patients IL-23R GA genotype improved overall survival (HR 0.48,
p 0.028) and, in the donor, decreased the risk of fungal
infections (p 0.05)
[8]
IL-4Ra
4679
A/C/G/T
40/56 ABPA IL-4Ra SNP associated with ABPA (p 0.008) [6]
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On the other hand, SNPs in the TLR-1 and TLR-6 genes and an
SNP in the promoter region of the TLR-9 gene have been found
to significantly influence the risk of IA and ABPA, respectively
[17,19]. Polymorphisms in the TLR-4 gene (Asp299Gly and
Thr399Ile) have been implicated in the responsiveness of
immune cell populations to Aspergillus species, and have been
associated with an increased risk of CCPA and IA [17,20]. In two
other studies, the Asp299Gly SNP appeared to play a role in
fungal colonization but not in fungal infection, whereas the
combined presence of TLR-4 1063A>G and INF-c 874T>A
increased the risk of IA in SCT patients [2].
Among soluble pattern recognition receptors, man-
nose-binding lectin (MBL) and surfactant A protein gene SNPs
seemed to influence the risk of invasive or chronic Aspergillus
infection [21]. CCPA and chronic necrotizing pulmonary
aspergillosis have been associated with a higher prevalence
of allele D in the MBL2 gene [22,23]. Additionally, the severity
of ABPA has been associated with the presence of a specific
SNP (1011A allele) in a polymorphic region in intron 1 of the
MBL2 gene, owing to elevated MBL plasma levels and
peripheral eosinophilia [24]. Similarly, surfactant A protein
gene SNPs have been associated with high concentrations of
IgE antibodies, peripheral eosinophilia, and deterioration in
lung function, and have been considered to be predisposing
factors for ABPA [25].
Immune Genetic Profile and Candidiasis
A delicate balance between Th1 and Th2 immunity is a
prerequisite for succesful Candida species recognition and
elimination. Impairment of cellular and/or humoral anti-Can-
dida immune responses, attributed mainly to genetic varia-
tions in key genes, has a significant immunomodulatory effect
on the susceptibility to Candida species, and these genetic
defects may serve as markers of predisposition (Table 2). A
multivariate analysis revealed that, among several cytokine
gene SNPs, only two, in the IL-10 and IL-12B genes, were
significantly associated with persistent candidaemia, owing to
decreased proinflammatory cytokine concentrations [26].
The immunomodulatory role of IL-4 in Candida infection
was evaluated by Choi et al. [27], who showed that specific
haplotypes of the IL-4 gene promoter region (–1098T/–
589C/–33C) were associated with a predisposition to
disseminated candidiasis in leukaemic patients, whereas
others (–1098T/–589T/–33T) were associated with protec-
tion. Furthermore, the IL-4 gene –589T/C SNP has also been
associated with an increased risk of vulvovaginal candidiasis
[28]. The role of TLRs in predisposition to Candida infections
has been also evaluated, and it was shown that specific SNPs
might have a protective role whereas others might have a
Table 1 (Continued)
Gene SNP
Patients/
controls
Aspergillus-related
disease Comments Reference
Interferon-c (IFN-c) 874T/A 44/64 IA after HSCT Combined presence of TLR-4 SNP and IFN-c 874T>A
SNP results in a trend towards increased susceptibility to
IA (p 0.04, OR 6.09, 95% CI 1.05–35.5)
[2]
874T/T IA SNP associated with IA (p <0.02) [1]
Plasminogen (PM) 28904A/G 83/147 IA after HSCT SNP associated with increased risk of IA (p <0.001,
OR 5.6)
[13]
Pulmonary surfactant
protein A (SPA-2)
1660A/G 10/11 ABPA AGA allele (A1660G) more frequent in patients with
ABPA than in controls (p 0.0156, OR 4.78, 95% CI
1.23–18.52)
[25]
SP-A2 G1649C resulted in a stronger association with
ABPA (p 0.008, OR 10.4, 95% CI 1.6–66.9)
Dectin-1 Y238X 205 HCST IA SNP increased susceptibility to IA; highest risk when SNP
was simultaneously present in both donors and recipients
(OR 3.9; p 0.005)
[15]
Y238X 71 IA after HSCT/
21 IA without HSCT
IA Allele frequency higher in non-HSCT patients with IA
(19.0% vs. 6.9–7.7%) (p <0.05)
[14]
SNP heterozygosity results in a trend towards IA
susceptibility without influencing clinical outcome
(OR 1.79; 95% CI 0.77–4.19, p 0.17)
DC SIGN Dectin-1
T/T G/G
DC-SIGN
A/G+G/G
C/T+T/T
G/A+A/A
G/C+C/C
57/182 IPA in haematological
patients
Dectin-1(T/T) and dectin-1(G/G) genotypes and DC-SIGN
(G), DC-SIGN(T), DC-SIGN(A) and DC-SIGN(C) alleles
increased the risk of IPA development (p 0.005)
[16]
ABPA, allergic bronchopulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; CF, cystic fibrosis; CNPA, chronic necrotizing pulmonary aspergillosis; HR, hazard
ratio; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis; IFN, interferon; IPA, invasive pulmonary aspergillosis; SCT, stem cell transplantation; TNFR,
tumour necrosis factor receptor; VNTR, variable number of tandem repeats.
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predisposing role. Nahum et al. [29] observed that the TLR-3
receptor gene variant allele L412F seems to increase the risk
of chronic mucocutaneous candidiasis (CMC). Increased
susceptibility to invasive candidiasis (IC) and candidaemia
has been also associated with the presence of specific SNPs
in the TLR-2 and TLR-4 genes [30,31]. A multivariate analysis
revealed that three TLR-1 gene SNPs (R80T, S248N, and
I602S) were significantly associated with candidaemia suscep-
tibility in Caucasians [32].
The C-type lectin receptor dectin-1 has been also
implicated in the early recognition and elimination of Candida
species. The dectin-1 Y238X early stop polymorphism was
associated in one study with an increased risk of gastroin-
testinal colonization with Candida species in immunocompro-
mised patients, whereas in another study the same SNP did
not significantly influence the risk of candidaemia [33,34]. A
modulating effect on Candida colonization has also been
associated with the presence of specific SNPs in the genes
encoding b-defensins, which are cationic peptides of
the epithelium that exert local antifungal activity. In particular,
the C/G SNP at position –44 seemed to have a protective
role against Candida colonization in diabetic and non-diabetic
patients [35]. In one study, increased risks of CMC
and recurrent vulvovaginal candidiasis were associated
with the presence of one SNP in the gene encoding
inflammasome component NALP3, which regulates IL-1b
production [36]. Finally, patients with specific
SNPs associated with a defective MBL2 gene showed
an increased risk of developing abdominal Candida infections
in secondary peritonitis, with recurrent vulvovaginal
candidiasis and with response to fluconazole treatment [37–
39].
TABLE 2. Single-nucleotide polymorphisms (SNPs) and Candida infection
Gene SNP
Patients/
controls Candida-related disease Comments Reference
Mannose-binding
lectin (MBL)2
Codon 54
Allele B
42/43 VVC Allele B associated with increased risk of VVC (p <0.0001) [38]
Codon 54
Allele B
109 RVC Variant allele B more frequent in patients with RVC than in controls
(20% vs, 6.6%, OR 3.4, 95% CI 1.3–8.2, p 0.01)
[39]
B alleles in 25% of 36 patients not suffering from any recurrence during
the maintenance therapy with decreasing doses of fluconazole vs.
controls (OR 4.9, 95% CI 1.9–12.5, p 0.0007)
B alleles in 20% of the 43 patients with sporadic recurrences vs. controls
(OR 3.6, 95% CI 1.4–9.2, p 0.007)
Allele D
Allele B
Allele C
88 Abdominal Candida infections Variant MBL genotype not associated with abdominal yeast infection
(53% vs. 38%, p 0.18)
[37]
Variant MBL genotype associated with yeast infection during early
peritonitis (39% vs. 16%, p 0.012)
Toll-like receptors
(TLRs)
TLR-1
R80T
S248N
I602S
338/351 Candidaemia Three TLR-1 SNPs (R80T, S248N, and I602S) associated with increased
susceptibility to candidaemia (p 0.02; p 0.04; p 0.02)
[32]
TLR-2
R753Q
325 Candidaemia in ICU patients Heterozygous TLR-2 SNP patients showed elevated TNF-a plasma
concentrations, but reduced IFN-c and IL-8 levels
[31]
TLR-4
D299G
Y399I
43/133 Candidaemia TLR-4 Asp299Gly SNP more frequently detected in patients with
candidaemia than in controls (26% vs. 10%; OR 3.0, 95% CI 1.3–6.9)
[30]
TLR-3
L412F
CMC Variant SNP associated with reduced IFN-c and TNF-a secretion in
response to stimulation with the TLR-3 ligand or Candida albicans
[29]
Dectin-1 Y238X 142 patients
with HSCT
Candida colonization Y238X SNP associated with increased risk of Candida colonization [33]
CARD9 Y238X
S12N
331/351 Candidaemia No association between dectin-1 SNP, CARD9 SNP and prevalence of
candidaemia (p >0.05)
[34]
Interleukin (IL) IL-4
–589T/C
42/43 VVC Increased susceptibility to VVC in women with IL-4 SNP [38]
IL-4
–1098T/G
–589C/T
–33C/T
40/43 CDC in leukaemia patients IL-4 (–1098T/–589C/–33C) haplotype associated with increased risk of
CDC development (p 0.01, OR 2.16)
[27]
IL-4 (–1098T/–589T/–33T) haplotype protective against CDC
development (p 0.018, OR 0.47)
IL-10
–1082A/G
IL-12B
2724
INS/DEL
338/351 Persistent candidaemia Persistent candidaemia associated with SNPs in IL-10 (OR 3.45,
95% CI 1.33–8.93) and IL-12B (OR 5.36, 95% CI 1.51–19.0)
[26]
b-Defensin-1 –44C/G 43/50 Candida carriage in
diabetic patients
SNP associated with Candida carriage in both groups (diabetic and
non-diabetic) (OR 25 for diabetic subjects and OR 8.5 for non-diabetic
subjects)
[35]
CARD9, caspase recruitment domain-containing protein 9; CDC, chronic disseminated candidiasis; CMC, chronic mucocutaneous candidiasis; HSCT, haematopoietic stem cell
transplantation; ICU, intensive-care unit; IFN, interferon; RVC, recurrent vulvovaginal candidiasis; TNF, tumour necrosis factor; VVC, vulvolvaginal candidiasis.
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Primary Immunodeficiencies (PIDs)
(monogenetic disorders) and Fungal
Infections
CMC
To date, several monogenetic disorders have been associated
with an increased susceptibility to CMC [40–43]. Primary
T-cell deficiencies, such as severe combined immunodeficiency
(SCID) and certain combined immunodeficiencies, are variably
associated with CMC in infancy, in addition to multiple
infectious and autoimmune diseases (Table 3). Furthermore,
CMC represents one of the main clinical presentations in
several rare PIDs associated with defective Th17 responses
[40–43].
Autosomal dominant hyper-IgE syndrome (HIES) was the
first syndrome in which impaired IL-17 immunity was
implicated in CMC susceptibility [44]. Autosomal dominant
HIES is caused by mutations in the gene encoding STAT3, a
signalling molecule downstream of the IL-23 receptor,
resulting in markedly reduced or absent IL-17 production
and increased susceptibility to CMC from the neonatal
period, in addition to severe skin and lung staphylococcal
infections [44,45].
Recently, Glocker et al. [46] described a single large
consanguineous family with autosomal recessive caspase
recruitment domain-containing protein 9 (CARD9) deficiency
and a history of recurrent CMC in addition to other fungal
infections, such as dermatophytosis and central nervous
system (CNS) candidiasis. All patients showed a significant
defect in the Th17 response, probably because of impaired
CARD9-dependent signalling downstream from several C-type
lectin receptors, such as dectin-1, dectin-2, and MINCLE,
which can recognize fungal pathogen-associated molecular
patterns. However, the underlying mechanism remains to be
elucidated [40,42]. Deep dermatophytosis was reported to be
an important manifestation of CARD9 deficiency [47].
Patients with autosomal recessive IL-12Rb1 and IL-12p40
deficiencies typically present with Mendelian susceptibility to
mycobacterial disease [48]. Approximately 25% of these
patients also show mild CMC, which may be the first
manifestation [49]. Some of these patients have low propor-
tions of IL-17-producing and IL-22-producing T-cells, probably
because of impaired IL-23 signalling [48,50]. CMC is the
‘signature’ disease and one of the earliest manifestations in
patients with autosomal recessive autoimmune polyendocrin-
opathy–candidiasis–ectodermal dystrophy [51]. It is caused by
TABLE 3. Primary immunodeficiencies (PIDs) associated with chronic mucocutaneous candidiasis (CMC)
PID CMC incidencea Other fungal infections Non-fungal infections
Cellular and
combined
SCID (>30 genes) X-linked or AR 30–35% Variable, depending on
immune deficit
Bacteria, viruses,
and mycobacteria
CIDs: DOCK8 deficiency (AR HIES)
NEMO or IKBa deficiency
MST1/STK4 deficiency
MHC class II deficiency
CD25 deficiency
TCR-a deficiency
CRACM1 deficiency
TYK2 deficiency (AR HIES)
Variable, depending on
immune deficit
High in DOCK8 (~80%)
Variable, depending on
immune deficit, mostly PCP,
cryptococcosis, and histoplasmosis
Viruses, bacteria,
and mycobacteria
(NEMO, CRACM1)
Idiopathic CD4 lymphopenia PCP
Cryptococcosis
Histoplasmosis
Viruses
PIDs with defective
Th17 immunity
STAT3 (AD HIES) 80% Aspergillosis
Cryptococcosis
Histoplasmosis
Bacterial (mostly
Staphylococcus aureus)
CARD9 AR Dermatophytes
CNS candidiasis
None
IL-12Rb1 and IL-12p40
(AR MSMD)
25–70% Invasive candidiasis
Histoplasmosis
Coccidioidomycosis
Paracoccidioidomycosis
Mycobacteria, Salmonella
AIRE (AR APECED) 90–100% None None
CMCD:
IL-17RA deficiency
IL-17F deficiency
STAT1 GOF mutation (AD)
None S. aureus
None S. aureus
Up to 100% PCP
Histoplasmosis
Coccidioidomycosis
Viruses
AD, autosomal dominant; AIRE, autoimmune regulator; APECED, autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy; AR, autosomal recessive; CARD9, caspase
recruitment domain-containing protein 9; CMCD, chronic mucocutaneous candidiasis disease; CNS, central nervous system; CRACM1, calcium release-activated calcium
modulator 1; GOF, gain-of-function; HIES, hyper-IgE syndrome; IL, interleukin; MHC, major histocompatibility complex; MSMD, Mendelian susceptibility to mycobacterial disease;
NEMO, nuclear factor-jB essential modulator; NK, natural killer; PCP, Pneumocystis pneumonia; SCID, severe combined immunodeficiency; STAT, signal transducer and activator
of transcription; TCR, T-cell receptor.
aData on CMC incidence are presented for PIDs for which this information is available.
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a mutation in the autoimmune regulator gene, resulting in
impaired T-cell tolerance. The associated CMC could not be
explained by the underlying mutation in the context of
autoimmunity until high levels of neutralizing autoantibodies
against Th-17 cytokines (IL-17A, IL-17F, and IL-22) were
detected in the sera of autoimmune polyendocrinopathy–
candidiasis–ectodermal dystrophy patients [52]. These findings
provided more evidence for the pivotal role of IL-17 immunity
in protection against CMC.
The pathogenesis of CMC was eventually deciphered in
2011, through investigations in patients suffering from CMC
disease (CMCD), which had an unknown genetic cause until
then [40]. The identification of complete autosomal recessive
IL-17RA and partial autosomal dominant IL-17F deficiencies in
pedigrees suffering from CMCD provided direct genetic
evidence for the role of IL-17 immunity in human susceptibility
to CMC [52]. Subsequently, gain-of-function mutations of
STAT1 were demonstrated to be the main cause of autosomal
dominant CMCD through genome-wide approaches [53,54].
These findings were confirmed by several other research
groups in almost 100 patients with CMCD and markedly
impaired IL-17 production, presumably as a result of impaired
dephosphorylation of STAT1, a signalling molecule down-
stream of the IFN type I/II, IL-23 and IL-12 receptors
[40,42,55]. Gain-of-function STAT1 mutations have also been
reported to predispose to disseminated dimorphic yeast
infections [55].
IFDs
Consistent with the immune mechanisms involved in human
host defence against fungi, IFDs occur with increased fre-
quency in patients with phagocytic, cellular and IFN-c–IL-12
axis immune defects [40,43,56]. Among PIDs, chronic granu-
lomatous disease and HIES are most frequently associated with
IFDs; variable susceptibility to IFDs is also seen in patients with
SCID, X-linked hyper-IgM syndrome, and other rare PID
syndromes (Table 4).
Invasive aspergillosis. Chronic granulomatous disease (CGD) is
the PID with the highest incidence of IFDs, mainly caused by
Aspergillus species [56,57]. IA accounts for over one-third of all
infections in CGD, and may be the presenting manifestation,
frequently occurring during the first two decades of life
[56,57]. An impaired respiratory burst in granulocytes and
monocytes underlies pulmonary aspergillosis in CGD [58].
IA also occurs in approximately 25% of patients with
autosomal dominant HIES, with 17% mortality. However,
susceptibility to IA, which always arises secondarily to
pneumatocyst formation or bronchiectasis resulting from
repeated bacterial pneumonias, is probably related to defective
STAT3 functions in lung epithelia, and not to impaired
phagocytosis [59]. Finally, IA has been occasionally encoun-
tered in autosomal recessive leukocyte adhesion deficiency
type 1, and, to a lesser extent, in congenital neutropenia
syndromes [40,41,56].
Invasive candidiasis. IC in PIDs is far less common than IA, and
has occasionally been reported in patients with certain innate
immune defects, such as CGD, severe congenital neutropenia,
and autosomal recessive leukocyte adhesion deficiency type 1
[41,56]. CNS Candida infections have been reported in CGD
patients and recently in three members of a consanguineous
family with autosomal recessive CARD9 deficiency [40,46].
This is the only PID predisposing to IC of the CNS, possibly as
a result of CARD9 expression predominantly on monocytes,
affecting their function [40,43].
Other IFDs. Dimorphic fungal diseases such as disseminated
histoplasmosis, coccidioidomycosis and paracoccidioidomyco-
sis have been reported in patients with mutations affecting the
IL-12–IFN-c axis and Mendelian susceptibility to mycobacterial
disease, such as IL-12Rb1 and autosomal dominant partial
IFN-cR1 deficiency [40,43,60]. In this patient group, fungal
susceptibility is consistent with preclinical studies suggesting the
important roles of IFN-c and IL-12 in host immune responses to
these organisms [56,61]. Similarly, patients with gain-of-function
STAT1 mutations have recently been reported with severe
disseminated dimorphic yeast infections, probably because of
aberrant regulation of IFN-c-mediated inflammation [55].
In addition, recent evidence suggests that genetic defects
in the IFN-c and/or granulocyte–macrophage colony-stimu-
lating factor signalling pathways may create a predisposition
to cryptococcosis, as has been described in a few patients
with neutralizing autoantibodies against IFN-c or granulo-
cyte–macrophage colony-stimulating factor [62,63]. Dissem-
inated histoplasmosis and cryptococcosis have also been
reported in patients with idiopathic CD4 lymphopenia,
X-linked CD40L deficiency, autosomal dominant HIES,
DOCK8 deficiency associated with autosomal recessive
HIES, and sporadic or autosomal dominant GATA2 defi-
ciency related to the recently described syndrome of
monocytopenia and susceptibility to mycobacteria, papillom-
aviruses, fungi, and myelodysplasia [40,41,64]. In addition to
IA, Paecilomyces, and, to a lesser extent, Scedosporium and
Trichosporon species have been occasionally implicated in
infections in CGD patients [41,56].
Pneumocystis pneumonia (PCP) occurs with variable fre-
quency in patients with profound T-cell deficiencies (SCID and
certain combined immunodeficiencies, such as NEMO,
DOCK8, caspase recruitment domain-containing protein 11
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and major histocompatibility complex class II deficiency), as
well as in patients with idiopathic CD4 lymphopenia, demon-
strating the crucial role of CD4 T-cells [40,41]. PCP also
occurs in approximately 50% of patients with X-linked
hyper-IgM syndrome caused by mutations in CD40L (which
is necessary for cooperation between T-lymphocytes and
B-lymphocytes and immunoglobulin class switch). In these
patients, PCP occurs at a median age of 1.3 years, and is often
the defining syndrome for a diagnosis of X-linked hyper-IgM
syndrome [65].
Comments
In the last few years, SNPs and inborn errors in distinct
immunological axes mediating susceptibility to specific fungi
have been recognized, providing valuable insights into human
immunity to fungal diseases and a rationale for developing new
approaches to their prevention and treatment. On the basis of
current knowledge, certain fungal diseases are highly sugges-
tive of specific PID types. Thus, CMC involves inborn errors in
IL-17 immunity, IA involves defects in the phagocyte NADPH
oxidase complex, disseminated endemic mycoses or cryp-
tococosis involve defects in the IFN-c–IL-12 axis, and deep
dermatophytosis and isolated CNS candidiasis have been
associated with CARD9 deficiency. Furthermore, several SNPs
have been associated with protection against IFD or a
predisposition to IFD. In contrast, the true impact of human
host genetics on the predisposition to IFDs and their
complications, based on genetic association studies, is not
yet established, and therefore host genetic data cannot yet be
applied in everyday clinical practice [66,67].
From a clinical point of view, extended knowledge on host
genetic polymorphisms associated with predisposition or
severity may eventually contribute to a better understanding
of the mechanism of disease, to the development of biomar-
kers, and to the prompt identification of high-risk individuals.
Furthermore, the detection of accurate biomarkers could help
to target individuals for prophylactic therapy, tailor supportive
care according to individual risk profiles, in order to ultimately
improve quality of life, reduce costs, and avoid unnecessary
and sometimes toxic antifungal therapy.
The question remains of what to do when one finds a
genetic defect or a specific polymorphism. In the case of some
main genetic defects, one can consider specific antifungal
prophylaxis and have a high degree of suspicion for IFDs. In
general, the transition from host genetics in IFDs to person-
alized medicine is a difficult issue, as data from both candidate
gene studies and whole genome association studies need to be
further validated with analytical and clinical sensitivity and
specificity procedures. However, with the advent of new
methods, such as next-generation sequencing, we may be able
to anticipate the discovery of more rare alleles that may have a
greater effect size and thus help to bridge the gap between
host genetics and clinics.
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